NEW YORK (GenomeWeb News) – The US Food and Drug Administration has told 23andMe that it must stop marketing its spit test and genome service to consumers because it has failed to address FDA's questions about the clinical and analytical validity of the product.

In a letter sent to company CEO Anne Wojcicki on Friday, the FDA said 23andMe must cease marketing the Saliva Collection Kit and Personal Genome Service to consumers immediately, and may not start marketing it again until it has received the agency's authorization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.